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Abstract Considerable progress has been made in rec-
ognizing microvesicles as important mediators of inter-
cellular communication rather than irrelevant cell debris.
Microvesicles released by budding directly from the cell
membrane surface (i.e., ectocytosis) either spontaneously
or in response to various stimuli are called shed vesicles
or ectosomes. Ectosomes are rightside-out vesicles with
cytosolic content, and they expose phosphatidylserine in
the outer leaflet of their membrane. Depending on their
cellular origin, ectosomes have been associated with a
broad spectrum of biological activities. In the light of
recent findings, we now know that ectosomes derived
from polymorphonuclear leukocytes, erythrocytes, plate-
lets, and tumor cells have profound effects on the innate
immune system, as well as on the induction of the
adaptive immunity, globally reprogramming cells such as
macrophages or dendritic cells toward an immunosuppressive
and possibly tolerogenic phenotype. Although the effects
observed in the circulation are mainly procoagulant and pro-
inflammatory, ectosomes might be anti-inflammatory/immu-
nosuppressive in local inflammation.
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Introduction
Over the last years, it became evident that communications
between cells relied not only on soluble mediators or cell–
cell contact, but also on the release of small vesicles by one
cell that transport information to another cell, which might
be in the vicinity or even at a distance. These vesicles are
described in the literature by multiple names including
microparticles (MP) or microvesicles. The messages trans-
mitted involve proteins, lipids, and nucleic acids. This type
of communication is not limited to multicellular organisms.
MP have been found in the matrix of bacterial biofilms and
to deliver signals critical for coordinating group behavior
(quorum sensing) [1, 2]. The evident advantages of vesicles
as messengers are: molecules inside the vesicles are
protected from the environment and those expressed at the
surface are in a conformation that allows multiple inter-
actions, thus more information can be provided. For
example, vesicles from platelets (PLT) provide the surface
necessary to induce thrombosis. Other aspects include the
transfer of molecules to the recipient cell, either on the cell
surface (e.g., transfer of tissue factor from vesicles of
monocytes to PLT) or that influence the expression of
proteins (e.g., RNA transfer that allows the expression of a
novel protein by the recipient cell).
Ectosomes—shed vesicles
Stein and Luzio coined the term ectocytosis to describe the
complement-triggered shedding of rightside-out plasma
membrane vesicles from the surface of polymorphonuclear
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leukocytes (PMNs) [3]. They wanted to clearly distinguish
the mechanisms related to “ectocytosis” from those of
exocytosis, which is used to describe the fusion of
intracellular secretory vesicles with the cell membrane
followed by the release of their content. Shed vesicles/
ectosomes are budding directly from the cell membrane
(Fig. 1) [4] and, for example, allow the removal of the C5b-
9 attack complex from the cell surface so assuring
protection against complement attack [3]. Such protective
function has been shown for PMNs, oligodendrocytes, and
even erythrocytes [5–7]. However, ectocytosis does not only
correspond to the removal of the C5b-9 complex, but also
allows a specific sorting of membrane proteins into the shed
ectosomes. Enrichment in cholesterol and diacylglycerol in
the ectosome membrane attests for a specific sorting of lipids
as well.
Although ectocytosis describes the same phenomenon in
many eukaryotic cells, the stimuli inducing cell membrane
budding can differ from one cell to another. Endothelial
cells, erythrocytes, and PMNs release ectosomes when
attacked by complement in vitro or exposed to other stimuli
[3, 8–10]. Monocyte-ectocytosis is induced by bacterial cell
wall components such as lipopolysaccharides (LPS),
whereas PLT release ectosomes by activation through
thrombin [11, 12]. Fibroblasts release ectosomes in
response to stress relaxation when cultured in a three-
dimensional collagen matrix [13]. Many cancerous cells
have an activated phenotype with highly active ectocytosis
in the absence of any stimulus [14, 15]. Indeed, the
shedding of ectosomes is enhanced when cells are
activated, ectocytosis is an ongoing process in vivo for
many cells, and background levels of ectosomes originating
from circulating and endothelial cells are found in blood [8,
9, 16, 17]. Physiological is the release of ectosomes by
chondrocytes which leads to bone formation [16]. Ectosomes
have often been associated with procoagulant and pro-
inflammatory effects. Those derived from endothelial cells
have been described to induce procoagulant activity in
monocytic cells [18], whereas ectosomes from PLT and
monocytes were shown to directly promote hemostasis and
induce inflammation by activating endothelial cells [12, 19].
Mackenzie et al. described the shedding of vesicles by
monocytes as a mechanism to release rapidly IL-1 [20].
Ectosomes serve as intercellular protein carriers for tissue
factor and the chemokine receptor CCR5 [21, 22]. The same
group reported on the anti-inflammatory properties of
ectosomes released by tumor cells, which suppressed B cell
activation and reduced the activation of monocytes induced
by LPS [23]. Finally, ectosomes have been proposed to be,
besides apoptotic cells, an important source of auto-antigens
[24], although in general apoptotic cells do not generate an
immune response and are well known to down-regulate the
inflammatory responses of monocytes and macrophages [25].
Ectosomes or soluble proteins?
Over the last 20 years, many reports described the release
of soluble proteins from the cell surface by enzymatic
cleavage. For instance, complement receptor 1 (CR1/CD35)
is cleaved from the surface of leukocytes by elastolytic
enzymes, and the large extracellular fragment of CR1 is
found in human plasma [26]. However, the same CR1
found in urine was not a soluble molecule but bound to
vesicles shed from glomerular epithelial cells (podocytes)
[27–31]. Electron microscopic pictures of the renal glomer-
ulus suggest that podocytes undergo under physiological
conditions, a continuous process of vesiculation by way of
ectocytosis, with the vesicles being released into the urinary
space. Recently, Hara et al. confirmed by electron and
immunoelectron microscopy using podocalyxin as bio-
marker of podocytes that apical cell membranes of
podocytes were shed into urine [32]. They showed that
podocalyxin-positive vesicles were similar in size to
podocyte microvilli, and the electron microscopy examina-
tion revealed a tip vesiculation of microvilli. This explains
Fig. 1 Ectosomes are microve-
sicles budding from the cell
membrane surface. a Small
membrane vesicles shed by
budding directly from the cell
membrane are called ectosomes.
b Detail of the shedding one
ectosome. PS that is normally in
the inner leaflet of the cell
membrane flips to the outer
membrane. The cell membrane
that loses its asymmetry shed
the formed vesicle/ectosome and
returns to its normal state.
However, the ectosome express
PS on its surface
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the release of CR1 bearing microvesicles in urine. While
analyzing different biological fluids (bronchoalveolar and
synovial fluids), it became evident that—as in urine and
different from the plasma—only a limited amount of the
total CR1 measured was soluble, the larger fraction being in
a “membrane” form, later found to be ectosomes released
by PMNs [33–38].
From the foregoing, it is evident that much attention has
to be given to the analysis of molecules measured in
biological fluids or in the supernatant of cell culture
experiments. Centrifugation and ultracentrifugation of these
fluids should always be performed so that vesicular bound
and soluble molecules can be distinguished.
PMN-derived ectosomes (PMN-Ect)
In accordance with the observations made by Stein and
Luzio [3], Hess et al. confirmed that the size, expression of
selective markers, and presence of phosphatidylserine (PS)
on the surface of vesicles released by PMNs activated with
fMLP or C5a correspond to the definition of ectosomes
[33]. By electron microscopy, it was possible to visualize
the formation of buds on activated PMNs and the newly
formed ectosomes, constituting a slightly heterogeneous
population of vesicles with a diameter of approximately 50
to 200 nm [33, 39]. The pattern of biotinylated proteins
between PMNs and PMN-Ect indicated a specific sorting of
proteins into and out of PMN-Ect at the time of their formation.
These ectosomes expressed a selective set of proteins
originating not only from the cell membrane (selectins and
integrins, complement regulators, HLA-1, FcγRIII, and
CD66b) but also from intracellular compartments (elastase,
myeloperoxidase/MPO, matrix metalloproteinase-9, and pro-
teinase 3). Thus, PMN-Ect do not correspond to inert particles,
but to small vesicles with effector activities such as immune
adherence and elastolysis [33, 39]. Particularly puzzling was
the presence of enzymes (elastase, MPO) on the surface of
PMN-Ect, which are normally localized in cellular granules.
Using MPO deficient cells, it was possible to demonstrate
that MPO was first released from activated cells in a soluble
form, and then bound back to PMN-Ect as well as to by-
standard cells [39, 40].
In vitro, PMN-Ect were found to specifically bind to
endothelial cells and phagocytic cells (monocytes/macro-
phages and the monocytic THP-1 cell line). In addition,
PMN-Ect were observed to bind specific proteins from
plasma, in particular C1q, which is followed by comple-
ment activation and C3 fixation [39, 41]. In whole blood,
PMN-Ect adhere to erythrocytes (complement-mediated
immune adherence) similarly to immune complexes
(Fig. 2) [41–44]. This immune adherence may allow
PMN-Ect to be removed rapidly from the circulation by
the fixed phagocytes of the liver, spleen, and bone marrow.
Together with this rapid clearance, the adherence of
ectosomes to erythrocytes may prevent binding to endothe-
lial cells, thus avoiding harmful fixation in tissues, for
instance glomeruli, as shown for apoptotic bodies and
immune complexes [43, 45]. However, the surface
expression of PS on PMN-Ect might have detrimental
effects in the blood circulation due to interactions with the
coagulation cascade. In vivo, PMN-Ect have been found
to be associated with platelet MP, which are well-known
catalyzers of thrombosis [46].
Fig. 2 Adherence of PMN-Ect
to erythrocytes in whole blood.
Representative FACScan dot
plots showing the binding of
PMN-Ect to anti-glycophorin A
(anti-gpA)-PE-labeled erythro-
cytes (Ery) in hirudine whole
blood. a Control fluorescence of
whole blood in the absence of
PMN-Ect. b Anti-gpA-PE-la-
beled erythrocytes in whole
blood in the absence of PMN-
Ect. c Anti-gpA-PE-labeled
erythrocytes in whole blood
incubated with fluorescent
PMN-Ect. d Anti-gpA-PE-
labeled erythrocytes in whole
blood incubated with fluorescent
PMN-Ect in the presence of
EDTA, which blocks
complement
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PMN-Ect express PS in the outer leaflet of their plasma
membrane similarly to apoptotic cells [39]. Of note, unlike
normal cells, ectosomes cannot restore this membrane
asymmetry over time [20, 39]. A detailed review on the
loss of the physiological asymmetry and its consequences is
given in another article of this issue [47]. The clearance of
apoptotic cells by phagocytes is dependent on a series of
interactions between the surface of the apoptotic cells and
the phagocyte. In addition, a series of soluble bridging
molecules are known to enhance this binding. One of these
molecules is C1q, which binds first to apoptotic bodies,
allowing them to be ingested more efficiently by macro-
phages [48–50]. In C1q deficient mice, apoptotic cells are
cleared improperly and with delay, which may be respon-
sible for autoimmunity [45]. As mentioned above, C1q also
binds PMN-Ect [39], and hence C1q binding may enhance
the uptake of these ectosomes by monocytes/macrophages.
The deposition of C3 fragments might have similar effects.
The next question is: do PMN-Ect modulate macrophage
function? Gasser et al. showed that tyrosine phosphoryla-
tion is enhanced in THP-1 cells after they have bound
PMN-Ect, suggesting the activation of one or more signal
transduction pathways [39]. In addition, when undifferen-
tiated THP-1 cells are incubated with PMN-Ect for 48 h,
they change their phenotype (down-regulation of CD14).
Gasser et al. found also that PMN-Ect induce the release of
TGF-β1 by human monocyte-derived macrophages in vitro
and are able to block macrophages’ inflammatory response
to zymosan A and LPS (down-regulation of IL-8, IL-10,
and TNFα secretion). Ectosome-to-cell contact is sufficient
for this immunomodulatory function, with PS expression
playing a central role [51]. The intracellular signaling
pathways involved in down-modulating macrophages have
been explored recently. The importance of Mer receptor
tyrosine kinase (MerTK) in the “tolerogenic” clearance of
apoptotic cells by macrophages and DCs was shown in in
vivo and in vitro studies [52–56]. Corresponding to these
observations, Eken et al. demonstrated that one of the major
mechanisms responsible for PMN-Ect-mediated down-
modulation of macrophages is the interaction of PMN-
Ect’ PS with MerTK (Fig. 3) [57], possibly via GAS6
secreted by macrophages [58]. Upon their encounter,
MerTK activates phosphatidylinositol 3-kinase (PI3K)/Akt
pathway, which in turn blocks NFκB p65 translocation to
the nucleus, and its phosphorylation thus opposes the
biological effects of TLR2 activation. Consequently, the
expression of key pro-inflammatory genes such as TNFα,
IL-1β, IL-6, IL-8, IL-10, and IL-12 and their protein
release are inhibited [57]. However, besides PS, other
molecules of the ectosomes might induce additional
signaling pathways responsible for the modulation of the
macrophage response (e.g., cell surface components or
soluble factors released by the target cells).
PMN-Ect have also biological effects on the differenti-
ation of human monocyte-derived dendritic cells (DCs)
[59], hence on the immune response. When immature DCs
are stimulated with LPS in presence of PMN-Ect, their
morphology, phagocytic activity, expression of cell surface
molecules (CD40, CD80, CD83, CD86, HLA-DP DQ DR,
and CCR7), cytokine release (IL-8, IL-10, IL-12p70,
TNFα, and TGF-β1) and capacity to induce T cell prolifer-
ation are altered. Together, these results suggest that PMN-Ect
might induce a tolerogenic phenotype in DCs, similarly to
what has been described for apoptotic cells [25, 60].
Taken together, these observations on macrophages and
DCs indicate that PMN-Ect have unique characteristics that
make them candidates for playing roles in inflammation
and immunity.
Here, we would like to emphasize the complexity of the
inflammatory process: on one hand, it needs to be amplified
so as to trigger a specific immune response, and on the
other hand, it has to limit excessive inflammation and
prevent autoimmunity. At the site of injury, whether this
injury is related to cell necrosis and/or infection, much
phagocytic and inflammatory activity is needed. However,
such local inflammation requires control as well and does
not need systematically the stimulation of an acquired
immune response. PMN-Ect are released at the early phase
of PMN activation and have the property of early down-
modulation, which in the local context may participate in
the control of autoimmune responses, similar to the effect
that has been suggested for apoptotic cells [25, 61–63].
However, a major difference between PMN-Ect and
apoptotic cells is that PMN-Ect are involved very early in
inflammation, a time point that might be crucial for
determining later aspects of the cascade responsible for
acquired immunity. Thus, PMN-Ect might not be involved
only in terminating inflammation, but also in controlling the
immune response.
It is noteworthy to highlight the effects of PMN-Ect on
resting cells. Exposing immature DCs to PMN-Ect alter
their morphology and their phagocytic activity [59], and in
macrophages, PMN-Ect induce the phosphorylation of Akt
[57]. Moreover, TGF-β1 is rapidly released by both cell
types upon PMN-Ect encounter [51, 59], an effect that
merits further investigation. Such encounter does not
induce apoptosis in the cells taking up ectosomes. To the
contrary, PMN-Ect actively change the biological behavior
of immature DCs and resting macrophages, suggesting that
PMN-Ect reprogram these cells immediately even in
absence of a specific stimulus.
In sum, PMNs, known to be central in inflammation,
release potent anti-inflammatory and immunosuppressive
effectors in the form of ectosomes at the earliest stage of
inflammation, already providing a drive to its resolution
[51, 57, 59].
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Erythrocyte-derived ectosomes (E-Ect)
In vivo, circulating erythrocytes lose 20% of hemoglobin
and membrane during aging by shedding vesicles.
Hemoglobin-containing ectosomes are known to circulate
in plasma [64]. Similar vesicles are produced during storage
of erythrocytes. Blood transfusion has different biological
effects in particular on the immune system. Post-operative
infections are increased in patients receiving blood trans-
fusions, suggesting that components of blood are immuno-
suppressive [65–67]. Opelz et al. [68] reported many years
ago that blood transfusion of cellular blood components
improved renal allograft survival in transplant patients. The
beneficial effect of blood transfusion on the number of
rejection episodes and survival of transplanted kidneys was
later confirmed [69, 70]. Other favorable effects of blood
Fig. 3 A schematic drawing of
the pathways involved in the
down-modulation of human
macrophages by PMN-Ect. a
Macrophages are activated by
the ligation of zymosan A to
TLR-2, which positively signals
NFκB translocation to the nu-
cleus and its subsequent phos-
phorylation that leads to
production of pro-inflammatory
cytokines. b PMN-Ect bind via
phosphatidylserine (PS) exposed
in the outer layer of their
membrane to Mer receptor
tyrosine kinase (MerTK),
possibly bridged by the ligand
GAS6 released by the
macrophages. Then, MerTK
activates PI3K/Akt, which in
turn inhibits NFκB transactiva-
tion. Thus, the transcription and,
consequently, the translation
of pro-inflammatory
cytokines are abrogated
Semin Immunopathol (2011) 33:487–495 491
transfusion have been described in autoimmune diseases,
such as reduced recurrence of Crohn’s disease [65]. Many
authors have related the immunosuppressive properties of
blood transfusion to one or the other component of blood,
with particular attention to the transfused leukocytes [67].
For instance, an increased incidence of infections has been
clearly associated with transfusion of non-leukocytes
depleted blood. This might be due to the immunological
reactions induced by “leukocyte transplantation” [71].
However, recent data suggest that the depletion of
leukocytes is not enough to remove the negative biological
properties of transfusion. The transfusion of leukocyte-
depleted erythrocytes does not improve the survival in
patients with colorectal cancer, and both types of trans-
fusions are worse than no transfusion [72]. Recently, Koch
et al. showed that in patients undergoing cardiac surgery,
transfusion of red cells that had been stored for more than
2 weeks was associated with a significantly increased risk
of post-operative complications as well as reduced short-
term and long-term survival [73]. In addition, Atzil et al.
have shown in a rat model that transfusion of fresh blood is
less harmful than transfusion of stored blood in the context
of progressing malignancies. Indeed, blood of either
allogeneic or syngeneic origin stored for 9 days or longer
significantly increased lung tumor retention in a storage
time-dependent manner. Fresh blood, allogeneic or synge-
neic, had no deleterious effect [74]. Less attention has been
given to other components of stored blood with respect to
immunosuppression. For instance, small vesicles/MP de-
rived from erythrocytes during storage are abundant in
packed erythrocytes, and their number increases with
storage time [3, 64, 75, 76]. Thus, immunological proper-
ties of these vesicles are of particular interest.
Erythrocyte-derived MP released during storage show
the characteristics of ectosomes, with a size between 50 and
500 nm, (Fig. 4) and the expression of erythrocyte surface
marker and PS. The protein pattern of erythrocytes
compared to that of E-Ect shows a specific sorting of
proteins into and out of E-Ect at the time of their formation
[77]. The work of Pascual et al. indicates that ATP-depleted
erythrocytes, mimicking aging of erythrocytes, lose prefer-
entially CR1 and DAF, which are both enriched in the
ectosomes [38]. The expression of these complement
regulators as well as CD59 might confer to E-Ect, a
resistance to complement attack. In plasma, E-Ect bind
C1q, which is followed by complement activation and C3
fixation. As already referred to, apoptotic cells as well as
apoptotic bodies express PS and bind C1q, which ensures a
more efficient phagocytosis by macrophages. The same
accelerated phagocytosis might be valid for E-Ect as well
[48, 49]. E-Ect exert an anti-inflammatory effect on
activated macrophages leading to a significant decrease,
almost abrogation of pro-inflammatory cytokines release
(TNFα, IL-8 as well as IL-10). This inhibitory effect is
immediate, a property shared with ectosomes of PMNs, and
sustained for up to 24 h. Differently from ectosomes of
PMNs, those of erythrocytes do not induce the release of
TGF-β1, whether the ectosomes are produced by aging
(ATP depletion), storage, or Ca++ ionophore.
It is to be expected that the properties of ectosomes are
directly dependent on the originating cell. Thus, the
biological difference observed for PMN- and E-Ect is not
surprising. In addition, any cell may release different types
of vesicles. For instance, PLT are known to release two
types of MP: (1) vesicles of 100 nm to 1 μm shed from
their surface (equivalent to ectosomes) and (2) preformed
exosomes released from multivesicular bodies measuring
40 to 100 nm in diameter [78]. The MP of PLT are
described in the literature mainly as promoting coagulation
via the exposure of PS. But does PS of platelet ectosomes
induce inflammation as well or is it—as for other
ectosomes and apoptotic cells—an element that controls
inflammation?
Platelet-derived ectosomes (PLT-Ect)
PLT transfusions are necessary to prevent bleeding in
thrombocytopenic patients. PLT concentrates used for
transfusion are stored up to 4 days, time during which they
shed large amounts of shed vesicles (ectosomes), which
express a high concentration of CD61 and no CD63 [78].
During their storage time, they acquire proteins from
plasma such as complement proteins C1q, factor H, and
C3 fragments [79]. Interestingly, in vitro, PLT-Ect have
similar effects on macrophages than those of PMNs; they
induce an immediate release of TGF-β1 and they reduce
the pro-inflammatory cytokine release. Thus, it is of interest
to realize that PLT-Ect have many faces including procoagu-
Fig. 4 Electron microscopy of E-Ect. Picture of a standard E-Ect
preparation showing heterogeneity in size, which ranged from 50 to
500 nm. Size bar, 200 nm
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lant activities, but also others that may dampen inflammation
under specific circumstances.
The fate of ectosomes
To date, little attention has been given to the fate of
ectosomes, once they have reached their target. First,
they might just remain adherent to the target cells, as
evidently observed for the binding of ectosomes to
erythrocytes in the presence of plasma. Second, they
might be integrated into the membrane by fusion as
described by Del Conde et al. [80]. These authors have
nicely showed that tissue factor on monocyte/macrophage-
derived microvesicles do not only bind activated PLT but
fuse with them through a mechanism involving P-selectin
glycoprotein ligand-1 on the microvesicles and P-selectin
and PS on the PLT. This fusion/integration transfers both
proteins and lipid to the platelet membrane and allows the
content to be put in immediate contact with the cytoplasm
of the target cell. Third, ectosomal proteins and lipids that
have been ingested by macrophages might be re-expressed at
the cell surface after having recycled in the cell. Whereas there
is evidence for ingestion, the re-expression has been postulat-
ed but not demonstrated. These three mechanisms are not
exclusive, and depending on the circumstances, the type of
ectosomes and target cell, one or the other might be preferred.
It is evident that depending on the type of incorporation,
transferred molecules might or might not transfer signaling
properties as well.
Concluding remarks
The biological roles of ectosomes might depend not only
on their intrinsic properties, but also on the site of their
formation. Evidently the high expression of PS on
ectosomes of PMNs, erythrocytes and PLT in the
intravascular compartment might help to promote a
prothrombotic state with all its ensuing consequences.
The anti-inflammatory properties described in this review
may thus be well masked, but may, on the other hand,
provide some limitation to the inflammatory process
induced by the coagulation and complement cascade. In
tissues, particularly for PMN-Ect, the situation will be
very different and such ectosomes are more likely to
encounter macrophages or DCs and limit their inflam-
matory/immune response activities, with a resulting
dominating anti-inflammatory effect.
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